Rare Tumors最新文献_第10页

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab. 地诺单抗治疗侵袭性成骨细胞瘤伴继发性动脉瘤性骨囊肿。

IF 0.9

Rare Tumors Pub Date : 2021-08-29 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211034710

Karlton Wong, Jomjit Chantharasamee, Scott Nelson, Mark A Eckardt, Kambiz Motamedi, Francis J Hornicek, Arun S Singh

{"title":"Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.","authors":"Karlton Wong, Jomjit Chantharasamee, Scott Nelson, Mark A Eckardt, Kambiz Motamedi, Francis J Hornicek, Arun S Singh","doi":"10.1177/20363613211034710","DOIUrl":"https://doi.org/10.1177/20363613211034710","url":null,"abstract":"Osteoblastomas and aneurysmal bone cysts (ABC) are rare benign bone tumors that make up about 1%-2% of primary bone malignancies, typically occurring in young patients with a median age of 20 years, most commonly effecting the axial skeleton. ABCs may develop independently as primary lesions, or secondary to other bony lesions including osteoblastomas, chondroblastomas, and giant cell tumors. Treatment of unresectable or extensive osteoblastomas can be challenging. In 2013, the Food and Drug Administration (FDA) approved denosumab for the treatment of giant cell tumors of the bone due to its efficacy in these morbid bony lesions. Various case reports have shown that osteoblastomas can respond to denosumab. Furthermore, numerous ABC case reports have described the efficacy of denosumab in these situations. We herein describe a unique case of a young patient with an aggressive osteoblastoma and secondary ABCs who was successfully treated with denosumab.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2021-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/5f/10.1177_20363613211034710.PMC8408893.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39388559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Choriocarcinoma metastatic to the skin: A rare occurrence associated with dismal outcome. 绒毛膜癌转移到皮肤:一种罕见的发生与令人沮丧的结果。

IF 0.9

Rare Tumors Pub Date : 2021-08-20 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211039724

Mousa ElKhaldi, Rakan Radi, Maysa Al-Hussaini

引用次数: 0

Olaratumab's failure in soft tissue sarcoma. 奥拉拉单抗在软组织肉瘤中的失败。

IF 0.9

Rare Tumors Pub Date : 2021-07-18 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211034115

Maroun Bou Zerdan, Aram H Bidikian, Ibrahim Alameh, Clara El Nakib, Hazem I Assi

{"title":"Olaratumab's failure in soft tissue sarcoma.","authors":"Maroun Bou Zerdan, Aram H Bidikian, Ibrahim Alameh, Clara El Nakib, Hazem I Assi","doi":"10.1177/20363613211034115","DOIUrl":"https://doi.org/10.1177/20363613211034115","url":null,"abstract":"Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care center in the Middle East and North Africa region. Monitor the effect of Olaratumab on sarcomas when it was used prior to its withdrawal, and compare our findings with the literature. We performed a retrospective analysis of adult patients with advanced-/metastatic soft tissue sarcomas treated with at least two cycles of Olaratumab at a tertiary care center in Lebanon during the period from January 1, 2017 to December 31, 2018. Fifteen patients were included in the study. The mean age was 49 with a range of 26-75 years. The median duration of the use of Olaratumab was 21.3 months with a range of 7.3-37 months. The average number of number of cycles received per patient was four. Five patients were deceased. Median PFS was 7.87 months (95% CI 5.28-10.45), and mean OS was 12.26 months (95% CI 8.47-16.05) Median OS was 9.8 months (95% CI 6.07-13.53). Olaratumab has been withdrawn from the market, and it is currently being investigated as part of the phase II ANNOUNCE 2 trial. Our experience from a tertiary care center shows results similar to those reported in the literature. The immunogenicity and heterogeneity of soft tissue sarcomas pose a challenge to the treatment of soft tissue sarcomas, but they also allow a wide array of possible management solutions.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2021-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/20363613211034115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39276934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rare case of chordoma presenting as a Pancoast tumor. 一例罕见的脊索瘤表现为Pancoast肿瘤。

IF 0.9

Rare Tumors Pub Date : 2021-07-02 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211029493

Philip T Sobash, Krishna Vedala, Daniel Alfano, Heather Pinckard-Dover, Jason L Muesse, Raman Desikan

引用次数: 0

Extragonadal germ cell tumor, a report of two cases presenting in the gastrointestinal tract. 生殖道外生殖细胞瘤2例报告。

IF 0.9

Rare Tumors Pub Date : 2021-06-30 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211029487

Mousa Elkhaldi, Ahamd Moayad Naser, Yazan AlHalaseh, Maysa Al-Hussaini

引用次数: 2

Undifferentiated pleomorphic sarcoma in oropharyngeal mucosa of patients with multiple basal cell carcinomas. 多发性基底细胞癌患者口咽黏膜中的未分化多形性肉瘤。

IF 0.9

Rare Tumors Pub Date : 2021-06-30 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211026483

Andrea Dekanić, Marko Velepič, Margita Belušić Gobić, Ita Hadžisejdić, Nives Jonjić

引用次数: 0

Breast erythema and nodular skin metastasis as the first manifestation of breast implant-associated anaplastic large cell lymphoma. 乳房红斑和结节性皮肤转移是乳房植入物相关间变性大细胞淋巴瘤的首要表现。

IF 0.9

Rare Tumors Pub Date : 2021-06-30 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211028498

Noellie Ducastel, Ioana-Mariana Cimpean, Ivan Theate, Olivier Vanhooteghem

引用次数: 2

Intraosseous ancient Schwannoma: A rare case in the mandible and a literature review. 骨内古老神经鞘瘤:下颌骨一例罕见病例并文献复习。

IF 0.9

Rare Tumors Pub Date : 2021-06-27 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211026480

Neda Kardouni Khoozestani, Maziar Motiee-Langroudi, Ali Salehi, Paniz Ranji

引用次数: 6

Histological scores and tumor size on stage II in adrenocortical carcinomas. 肾上腺皮质癌II期的组织学评分和肿瘤大小。

IF 0.9

Rare Tumors Pub Date : 2021-06-27 eCollection Date: 2021-01-01 DOI: 10.1177/20363613211026494

Rui Caetano Oliveira, Maria João Martins, Carolina Moreno, Rui Almeida, João Carvalho, Paulo Teixeira, Miguel Teixeira, Edgar Tavares Silva, Isabel Paiva, Arnaldo Figueiredo, Maria Augusta Cipriano

{"title":"Histological scores and tumor size on stage II in adrenocortical carcinomas.","authors":"Rui Caetano Oliveira, Maria João Martins, Carolina Moreno, Rui Almeida, João Carvalho, Paulo Teixeira, Miguel Teixeira, Edgar Tavares Silva, Isabel Paiva, Arnaldo Figueiredo, Maria Augusta Cipriano","doi":"10.1177/20363613211026494","DOIUrl":"https://doi.org/10.1177/20363613211026494","url":null,"abstract":"Adrenocortical carcinomas (ACC) are aggressive tumors with a poor prognosis. Histological scores are advised for the diagnosis, however, there are borderline cases that may be misjudged as adrenocortical adenomas (ACA). The three main scores used are: Weiss Modified System (WMS), Reticulin Algorithm (RA), and Helsinki Score (HS). We intend to compare the accuracy of the three scores in ACC diagnosis and to identify predictive factors of overall survival (OS). Retrospective study (2004-2016) at Centro Hospitalar e Universitário de Coimbra of the adrenal tumors, classified as ACC or ACA, with a history of posterior tumor relapse/metastases, without lesions in the contralateral adrenal gland: 13F and 6M, with a median age of 51 ± 12.41 years. Nodules' median size was 9.20 ± 6.2 cm. Patients had a median OS of 52 ± 18.6 months, with 57.9% and 46.3%, at 3 and 5 years. Seven patients had local recurrence and nine had metastases. Thirteen cases were in stage II. The WMS and the HS allowed a diagnosis of ACC in 15 cases and the RA defined ACC in 17 cases. All cases had, at least, focal disruption of the reticulin framework. More than 5 mitosis/50 HPF was associated with worse OS: 49.67 ± 21.43 versus 108.86 ± 14.02 months (p = 0.026). In patients with stage II, tumor size ⩾10 cm was associated with worse OS: 19.25 ± 7.15 versus 96.11 ± 16.7 months (p = 0.007), confirmed by multivariate analysis (p = 0.031). The correct diagnosis of ACC is a pathologist responsibility. The RA seems the most accurate. Any loss of the reticulin framework should raise awareness for malignancy. In patients on stage II, a size ⩾10 cm is a predictor of worse prognosis.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2021-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/20363613211026494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39185382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A case report of imiquimod topical therapy as treatment for cutaneous metastasis of breast cancer. 咪喹莫特局部治疗乳腺癌皮肤转移1例报告。

IF 0.9

Rare Tumors Pub Date : 2021-06-24 eCollection Date: 2021-01-01 DOI: 10.1177/2036361320975748

Anthony L Nguyen, Esther G Chong, Joanne Lee, Saied Mirshahidi, Hamid Mirshahidi

引用次数: 3